Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alkermes ( (ALKS) ) has shared an update.
On July 21, 2025, Alkermes announced positive topline results from its Vibrance-1 phase 2 study, which evaluated the safety and efficacy of alixorexton in patients with narcolepsy type 1. The study demonstrated that alixorexton significantly improved wakefulness and patient-reported outcomes related to disease severity, fatigue, and cognition compared to placebo. These results support the advancement of alixorexton to phase 3 development, highlighting its potential as a transformative treatment in the narcolepsy market.
The most recent analyst rating on (ALKS) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.
Spark’s Take on ALKS Stock
According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.
Alkermes’ overall stock score is driven by its strong financial performance and positive earnings call insights. Weak technical indicators and modest valuation impact the score, while recent corporate events provide moderate support.
To see Spark’s full report on ALKS stock, click here.
More about Alkermes
Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products aimed at treating various neurological conditions.
Average Trading Volume: 1,687,656
Technical Sentiment Signal: Buy
Current Market Cap: $4.82B
Learn more about ALKS stock on TipRanks’ Stock Analysis page.